These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 15261431)
1. Pathology of malignant mesothelioma. Van Marck E Lung Cancer; 2004 Aug; 45 Suppl 1():S35-6. PubMed ID: 15261431 [TBL] [Abstract][Full Text] [Related]
2. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens. Kimura N; Dota K; Araya Y; Ishidate T; Ishizaka M Diagn Cytopathol; 2009 Dec; 37(12):885-90. PubMed ID: 19572412 [TBL] [Abstract][Full Text] [Related]
3. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma. Ylagan LR; Zhai J Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333 [TBL] [Abstract][Full Text] [Related]
4. D2-40: a reliable marker in the diagnosis of pleural mesothelioma. Müller AM; Franke FE; Müller KM Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767 [TBL] [Abstract][Full Text] [Related]
5. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. Cury PM; Butcher DN; Corrin B; Nicholson AG J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583 [TBL] [Abstract][Full Text] [Related]
6. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma. Suster S; Moran CA Adv Anat Pathol; 2006 Nov; 13(6):316-29. PubMed ID: 17075297 [TBL] [Abstract][Full Text] [Related]
7. Parathyroid hormone-related protein antigen localization distinguishes between mesothelioma and adenocarcinoma of the lung. Clark SP; Chou ST; Martin TJ; Danks JA J Pathol; 1995 Jun; 176(2):161-5. PubMed ID: 7636626 [TBL] [Abstract][Full Text] [Related]
8. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584 [TBL] [Abstract][Full Text] [Related]
9. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Deniz H; Kibar Y; Güldür ME; Bakir K Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998 [TBL] [Abstract][Full Text] [Related]
11. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Afify AM; Stern R; Michael CW Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337 [TBL] [Abstract][Full Text] [Related]
13. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy. Kobzik L; Antman KH; Warhol MJ Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121 [TBL] [Abstract][Full Text] [Related]
14. The role of immunohistochemistry in the diagnosis of malignant mesothelioma. Moran CA; Wick MR; Suster S Semin Diagn Pathol; 2000 Aug; 17(3):178-83. PubMed ID: 10968703 [TBL] [Abstract][Full Text] [Related]
15. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis. Cakir E; Demirag F; Aydin M; Unsal E Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123 [TBL] [Abstract][Full Text] [Related]
16. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation. Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489 [TBL] [Abstract][Full Text] [Related]
17. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium. Gulyás M; Hjerpe A J Pathol; 2003 Apr; 199(4):479-87. PubMed ID: 12635139 [TBL] [Abstract][Full Text] [Related]
18. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S J Clin Pathol; 2013 Oct; 66(10):847-53. PubMed ID: 23814259 [TBL] [Abstract][Full Text] [Related]